Azitra (AZTR) Return on Capital Employed (2023 - 2026)
Azitra's (AZTR) quarterly Return on Capital Employed came in at 168.52% in Q1 2026, up 3929.0% YoY from 4.18% in Q1 2025, and up 44.96% on a QoQ basis from 306.18% in Q4 2025.
Azitra (AZTR) Return on Capital Employed (2023 - 2026) Analysis & Trends
Azitra (AZTR) has 4 years of Return on Capital Employed data on file, last reported at 168.52% in Q1 2026.
- Quarterly Return on Capital Employed rose 3929.0% year-over-year to 168.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 168.52% (up 3929.0% YoY) and the FY2025 annual result came in at 214.02%, up 1195.0% from the prior year.
- Return on Capital Employed climbed to 168.52% in Q1 2026, from 306.18% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 106.55% in Q3 2023 to a low of 481.22% in Q3 2025.
- A 4-year average of 238.64% and a median of 204.28% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 27944 bps — and 2026, when it soared 3929 bps.
- Tracing AZTR's Return on Capital Employed over 4 years: stood at 158.53% in 2023, then climbed by 4 bps to 152.73% in 2024, then plunged by 100 bps to 306.18% in 2025, then soared by 45 bps to 168.52% in 2026.
- The last three Return on Capital Employed figures came in at 168.52% (Q1 2026), 306.18% (Q4 2025), and 481.22% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 7.88% |
| 10 | Azitra | 2.63 Mn | 2.63 Mn | - | -137.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -137.71% |
| Mar 31, 2026 | -168.52% |
| Dec 31, 2025 | -306.18% |
| Sep 30, 2025 | -481.22% |
| Jun 30, 2025 | -325.75% |
| Mar 31, 2025 | -207.81% |
| Dec 31, 2024 | -152.73% |
| Sep 30, 2024 | -201.78% |
| Jun 30, 2024 | -311.67% |
| Mar 31, 2024 | -204.28% |
| Dec 31, 2023 | -158.53% |
| Sep 30, 2023 | -106.55% |